Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Sana Biotechnology, Inc. (SANA) had Consolidated Net Income/Loss of $-49.39M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-49.39M |
|
-- |
|
-- |
|
$50.63M |
|
$-50.63M |
|
$1.24M |
|
$-49.39M |
|
$-49.39M |
|
$-49.39M |
|
$-49.39M |
|
|
Consolidated Net Income/Loss |
$-49.39M |
$-49.39M |
|
$-50.63M |
|
$-46.98M |
|
237.58M |
|
237.58M |
|
$-0.21 |
|
$-0.21 |
|
| Balance Sheet Financials | |
$112.73M |
|
$73.69M |
|
$332.74M |
|
$445.47M |
|
$33.16M |
|
-- |
|
$203.24M |
|
$236.39M |
|
$209.08M |
|
$9.26M |
|
$209.08M |
|
225.46M |
|
| Cash Flow Statement Financials | |
$-48.66M |
|
$16.60M |
|
$0.98M |
|
$131.40M |
|
$100.33M |
|
$-31.07M |
|
$7.02M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.40 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-48.54M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-23.62% |
|
-533.53% |
|
-11.09% |
|
-23.62% |
|
$0.93 |
|
$-0.20 |
|
$-0.20 |
|